[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"postural-orthostatic-tachycardia-syndrome-pots\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:postural-orthostatic-tachycardia-syndrome-pots":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,46,70,96,140,185,206,240,261,288],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":23,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100642514","presentation-of-young-adults-with-and-without-joint-hypermobility-100642514",false,"NCT07657507","Presentation of Young Adults With and Without Joint Hypermobility","Prospective Study of Symptoms in People With and Without Joint Hypermobility","Inclusion Criteria: Clarkson University Health Sciences students. -\n\nExclusion Criteria: Other physical conditions that preclude collecting \\>25% of physical measurements at initial data collection.\n\n\\-",true,"ALL","18 Years","60 Years",{"count":21,"type":22},100,"ESTIMATED","5 Years","OBSERVATIONAL","People with multiple hypermobile joints are diagnosed with Generalized Joint Hypermobility (GJH) when asymptomatic, or Hypermobile Ehlers-Danlos Syndrome (hEDS) and Hypermobility Spectrum Disorder (HSD) when symptomatic (hEDS\u002FHSD, or 'HSD' here). GJH likely affects about 20% of the U.S. population, while HSD affects 0.5-3% of the US population. Although joint hypermobility is the most visible presentation of HSD, it is a systemic connective tissue disorder affecting multiple body systems. Due to frequent health concerns, HSD may contribute to more than 30% of patients in chronic pain, rheumatology, orthopedic and physical therapy clinics. It is still unclear why some people have asymptomatic hypermobility and others develop complex chronic health issues. However, recent research suggests that the transition might be triggered by severe physiological stress, such as viral infection.\n\nHSD is commonly associated with Postural Orthostatic Tachycardia Syndrome (POTS) and Mast Cell Activation Syndrome (MCAS), as well as gastrointestinal (GI) problems. Recent research suggests that persistent inflammation due to MCAS or COVID may trigger HSD symptoms. The correlation between POTS and HSD may be due to effects of HSD on the autonomic nervous system or to inflammation triggering both conditions. It is also unclear whether body awareness and coordination deficits seen in symptomatic HSD are due to the fundamental connective tissue disorder or due to pain and injuries in HSD. This study seeks to determine whether asymptomatic hypermobile individuals (GJH) also have balance and coordination deficits. The current study hopes to identify factors that correlate with a transition from asymptomatic GJH to symptomatic HSD by following a group of Health Science students forward in time. The study will collect baseline health information including relevant diagnoses, symptoms and function. Physical measurements will include standard clinical tests performed by physical therapists: joint hypermobility and instability, standing balance, neck movement control, and heart rate in response to standing from lying down. The study is likely to last for at least 10 years to follow participants over time.",[27,28],"Hypermobile Ehlers-Danlos Syndrome","Postural Orthostatic Tachycardia Syndrome (POTS)",[30,31,32],"hypermobile Ehlers-Danlos Syndrome","Hypermobility Spectrum Disorders","Risk factors","NOT_YET_RECRUITING","2026-06-17",{"date":36,"type":37},"2026-06-22","ACTUAL",{"date":39,"type":22},"2026-06-20",{"date":41,"type":22},"2036-06-20",{"name":43,"class":44},"Clarkson University","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":56,"phases":57,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":4},"100637535","phase-2-beta-3-enhanced-autonomic-therapy-for-pots-100637535","NCT07585513","Beta-3 Enhanced Autonomic Therapy for POTS","A Randomized Placebo-Controlled Clinical Trial Evaluating Mirabegron's Effectiveness in Alleviating POTS Symptoms","BEAT-POTS","Inclusion Criteria:\n\n1. Provision of a signed and dated informed consent form.\n2. Male or female, age ≥ 18 years old.\n3. Confirmed POTS diagnosis, which includes chronic (\\>3 months) orthostatic intolerance, an increase in heart rate (HR) of ≥30 beats per minute (bpm) without orthostatic hypotension (\\>20 mmHg drop of systolic BP) during orthostatic tests.\n\nExclusion Criteria:\n\nAn individual who meets any of the following criteria will be excluded from participation in this study:\n\n1. Patients who are pacemaker-dependent because the pacing artifacts will complicate skin sympathetic nerve activity (SKNA) analysis.\n2. Clinically unstable (for example, acute myocardial infarction, decompensated heart failure, undergoing cancer chemotherapy, and other acute illnesses requiring hospitalization)\n3. Uncontrolled hypertension (systolic blood pressure ≥180 mm Hg or diastolic blood pressure ≥110 mm Hg, or both)18\n4. Active thyrotoxicosis\n5. Any experimental medication concomitantly or within 4 weeks of participation in the study\n6. Currently participating in a different clinical trial\n7. Severe renal impairment (CrCl \\\u003C 30 ml\u002Fmin)\n8. Hepatic disease (Child-Pugh Class C)\n9. Prisoners\n10. Pregnant\n11. Breastfeeding\n12. Cannot speak, write, or answer questions in English (Validated symptom questionnaires used in this study are available only in English.)\n13. Does not have the capacity to consent\n14. Patients who are known to be allergic to mirabegron or skin patch electrodes\n15. Patients taking codeine, oxycodone, thioridazine, flecainide, propafenone, and digoxin. (see explanation below)",{"count":55,"type":22},36,"INTERVENTIONAL",[58],"PHASE2","The study will test the hypothesis that mirabegron is more effective than a placebo in alleviating postural orthostatic tachycardia (POTS) symptoms.",[28],"2026-05-09",{"date":63,"type":37},"2026-05-13",{"date":65,"type":22},"2026-05",{"date":67,"type":22},"2028-05",{"name":69,"class":44},"Cedars-Sinai Medical Center",{"id":71,"slug":72,"hasResults":11,"nctId":73,"briefTitle":74,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":78,"targetDuration":4,"studyType":56,"phases":80,"briefSummary":82,"conditions":83,"keywords":84,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":4},"100594991","avnt-in-pots---pilot-100594991","NCT07026643","aVNT in POTS - Pilot","Auricular Vagal Neuromodulation Therapy in Postural Orthostatic Tachycardia Syndrome: Physiological Mechanisms and Systemic Effects - A Pilot Study","Inclusion Criteria:\n\n* POTS Patients: POTS patients will meet Canadian Cardiovascular Society criteria. 6 POTS patients will have orthostatic tachycardia \\>30 bpm increase in HR within 10 minutes of upright posture \\[\\>40 bpm in patients \\\u003C20 years\\]), in the absence of orthostatic hypotension (drop in BP \\>20\u002F10 mmHg), chronic symptoms of orthostatic intolerance, and no obvious cause for the tachycardia.\n* Age between 18-80 years\n* Male and female subjects are eligible\n* Able and willing to provide informed consent\n\nExclusion Criteria:\n\n* Unable to give informed consent\n* Stimulant use within one week of the study\n* Systolic blood pressure \\>150 mm Hg and\u002For diastolic blood pressure \\> 100 mm Hg\n* Neurogenic orthostatic hypotension, prior stroke, myocardial infarction or heart failure, hematocrit \\\u003C 28%\n* Significant comorbidities (cardiovascular, metabolic, renal, respiratory, cancer, immunological or hematological)\n* History of vagotomy, permanent pacemakers\n* Pregnant or nursing females.","80 Years",{"count":79,"type":22},30,[81],"NA","Autonomic nervous system imbalance causes postural tachycardia and related cardiac symptoms in Postural Orthostatic Tachycardia Syndrome (POTS). The impact of POTS is more far-reaching than postural tachycardia. Several systemic, autonomic symptoms along with neuro-cognitive dysfunction leading to poor quality of life contribute to significant disability in POTS. A combination of abnormal autonomic tone, abnormal cerebral blood flow regulation, and systemic inflammation may contribute to POTS symptoms.\n\nAuricular Vagal Neuromodulation Therapy (aVNT) has the potential for multisystem holistic benefit for patients with POTS: Autonomic neuromodulation by aVNT might address multiple aspects of POTS pathophysiology and improve POTS symptoms. It can reduce postural tachycardia by increasing the parasympathetic (PNS) and decreasing sympathetic (SNS) tone. In patients undergoing vagus nerve stimulation for various indications, an increase in PNS tone has been associated with improved middle cerebral artery velocity (MCAv) at rest and during cognitive stress. aVNT has been associated with improved cerebral blood flow and reduced infarct size in an experimental model of ischemic stroke, suggesting similar improvements in cerebral autoregulation in POTS. Vagus nerve stimulation has also been linked to improved cognitive function. The anti-inflammatory effect and improved endothelial function might improve cerebral blood flow regulation and cognitive function. The anti-inflammatory effects of aVNT may improve postural hemodynamics, reduce postural tachycardia, relieve other POTS symptoms, and improve quality of life (QoL). POTS is a complex multisystem disorder with debilitating symptoms that currently lack effective treatments. aVNT has the potential to recalibrate autonomic tone dysregulation, enhance MCAv, improve cognitive function, reduce inflammation, and ultimately improve symptoms and quality of life in POTS patients.",[28],[85,86],"Postural Orthostatic Tachycardia Syndrome","Auricular vagal neuromodulation therapy","2026-04-30",{"date":89,"type":37},"2026-05-01",{"date":91,"type":22},"2026-09-01",{"date":93,"type":22},"2031-12-31",{"name":95,"class":44},"University of Calgary",{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":56,"phases":105,"briefSummary":106,"conditions":107,"keywords":125,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":131,"lastUpdatePostDateStruct":132,"startDateStruct":134,"completionDateStruct":136,"leadSponsor":138,"locationsCount":45},"100629707","effects-of-whole-body-electrical-muscle-stimulation-exercise-on-adults-with-neuromuscular-disease-100629707","NCT07478172","Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease","Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults withNeuromuscular Disease","Inclusion Criteria:\n\n* Age 18 or older\n* Diagnosed with one or more of the following neuromuscular conditions: Amyotrophic lateral sclerosis, primary lateral sclerosis, progressive muscle atrophy, spinal muscular atrophy, postpolio syndrome, inclusion body myositis, pompedisease, fascioscapulohumeral muscular dystrophy, charcot marie tooth disease, chronic inflammatory demyelinating polyneuropathy, hereditary spastic paraplegia, myasthenia gravis, lambert-eaton myasthenic syndrome, postural orthostatic tachycardia syndrome, mitochondrial myopathy, nemaline myopathy, centronuclear myopathy, lumbar radiculopathy, non-specific low back pain.\n* Ability to stand for approximately 15 minutes continuously with or without an assistive device (i.e. the length of time to stand to take a shower, complete meal preparation, wait in line at the bank, etc.)\n* At least some anti-gravity strength in major muscle groups as assessed by manual muscle testing (i.e. 2+\u002F5 strength or better)\n* Medical clearance to participate in an exercise program\n* Ability to provide informed consent\n* Ability to conform to the requirements of the study (i.e. attendance at assessment and intervention visits, maintain current level of non-study physical activity for the duration of the study, no intention to relocate mid-study)\n\nExclusion Criteria:\n\n* Diagnosed with one of the following neuromuscular conditions: Becker's muscular dystrophy, Duchenne muscular dystrophy, limb-girdle muscular dystrophy, myotonic dystrophy type 1 or 2, Freidrich's ataxia, any other NMD with known or suspected cardiac involvement or muscle fiber structural integrity defects.\n* Concurrent participation in another interventional research study\n* Unable to tolerate 15 minutes of continuous standing with or without an assistive device\n* Presence of a pacemaker, metal implants, or other implanted medical devices that could impact participant safety during WB-EMS intervention\n* Presence of cochlear implant, cortical stimulator, deep brain stimulator, ventriculoperitoneal shunt, recent skull defect, seizure in the past 12 months while taking anti-epilepsy medication, or previous serious adverse event with TMS, which could impact participant safety during TMS testing\n* Presence of unstable acute or chronic disease (i.e. renal failure, rheumatologic disease, cardia arrhythmia, neoplasm, uncontrolled hypertension)\n* Known pregnancy at time of screening; verbal screening will occur throughout the study.\n* Presence of a terminal disease (i.e. receiving hospice services)\n* Current or previous use of any drugs known to influence muscle mass or performance within 6 months; these may include but are not limited to anabolic steroids, IGF01, growth hormone, replacement androgen therapy, anti-androgen therapy\n* Presence of an additional neurologic conditions affecting somatosensory or motor function\u002Fcontrol (i.e. Parkinson's disease, Multiple Sclerosis, h\u002Fo stroke, TBI, SCI, ataxia, apraxia, hemiplegia, etc.)\n* Musculoskeletal condition or surgery in the past year that would confound results of exercise interventions (i.e. TKA, THA, RTC repair, spinal fusion)\n* Other medical conditions, signs, or symptoms that would interfere with study conductor interpretation of results as determined by an investigator",{"count":104,"type":22},50,[81],"This single-arm pilot study evaluates the effects of whole-body electrical muscle stimulation (WB-EMS) exercise on neuromuscular and physical function in adults with neuromuscular disease (NMD). Due to motor unit impairments, NMD patients often cannot tolerate traditional exercise. WB-EMS bypasses voluntary activation limits by directly stimulating muscle contractions. Up to 50 adults with conditions like ALS, SMA, and MG will undergo 20-minute supervised WB-EMS sessions (1-2 times weekly for 4-8 weeks) using the Katalyst system. Outcomes include neural excitability (TMS), motor unit behavior (EMG, NCS), functional tests (walk, balance, strength), and patient-reported fatigue, pain, and quality of life. Strict safety monitoring and exclusion criteria are in place. This study will provide preliminary data on WB-EMS as a potential exercise modality for NMD.",[108,109,110,111,112,113,114,115,116,117,118,119,120,121,122,123,28,124],"Neuromuscular Diseases (NMD)","Amyotrophic Lateral Sclerosis","Myasthenia Gravis","Lambert-eaton Myasthenic Syndrome","Primary Lateral Sclerosis","Spinal Muscular Atrophy","Charcot Marie Tooth Disease (CMT)","Fascioscapulohumeral Muscular Dystrophy","Inclusion Body Myositis","Mitochondrial Myopathy","Nemaline Myopathy","Centronuclear Myopathy","Postpolio Syndrome","Pompe Disease (Late-onset)","Chronic Inflammatory Demyelinating Polyneuropathy","Hereditary Spastic Paraplegia","Progressive Muscular Atrophy",[126,127,128,129],"Neuromuscular Disease","Electrical Stimulation","Whole Body stimulation","Exercise intervention","RECRUITING","2026-03-12",{"date":133,"type":37},"2026-03-17",{"date":135,"type":37},"2026-03-10",{"date":137,"type":22},"2031-01-07",{"name":139,"class":44},"University of Missouri-Columbia",{"id":141,"slug":142,"hasResults":11,"nctId":143,"briefTitle":144,"officialTitle":145,"acronym":146,"eligibilityCriteria":147,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":148,"targetDuration":150,"studyType":24,"phases":4,"briefSummary":151,"conditions":152,"keywords":165,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":181,"leadSponsor":182,"locationsCount":45},"100608041","polish-registry-of-cardioneuroablation-and-cardioneuromodulation-100608041","NCT07196397","POLish Registry of CArdioneuroablation and CArdioneuromodulation","POL-CA Registry: Multicenter Observational Study of Neuromodulatory Procedures in Cardiovascular Autonomic Dysfunction Syndromes","POL-CA","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Diagnosis of at least one of the following conditions:\n\n  * Inappropriate sinus tachycardia (IST)\n  * Postural orthostatic tachycardia syndrome (POTS)\n  * Vasovagal syncope (VVS)\n  * Cardioinhibitory carotid sinus syndrome (CSS)\n  * Symptomatic sinus bradycardia or functional AV block\n  * Orthostatic hypotension (OH)\n* History of recurrent autonomic symptoms (e.g., syncope, bradycardia, palpitations, orthostatic intolerance)\n* Undergoing or previously underwent interventional treatment affecting cardiac autonomic innervation (e.g., cardioneuroablation, SN-sparing ablation, cardiac sympathetic denervation)\n* Provided written informed consent (for prospective arm)\n\nExclusion Criteria:\n\n* Structural heart disease requiring surgical intervention\n* Permanent pacemaker or ICD implanted prior to enrollment\n* Inability to complete follow-up assessments or questionnaires\n* Severe psychiatric comorbidities impairing participation\n* Participation in another interventional clinical trial",{"count":149,"type":22},1000,"3 Years","The multicentre observational study POL-CA involves a wide spectrum of patients with a history of syncopy. The study recruits patients with diagnosed vasovagal syndrome, cardioinhibitory carotid sinus syndrome, symptomatic sinus bradycardia or atrioventricular block, postural orthostatic tachycardia syndrome, orthostatic hypotension, and inappropriate sinus tachycardia syndrome. This is an observational, controlled study with retrospective, clinical data analysis of previously treated patients and the analysis of syncopal patients prospectively recruited into the study. The aim of the POL-CA registry is to create a platform for physicians to record treatment data for patients undergoing procedures that affect innervation or modify cardiovascular reflexes (cardioneuroablation, cardioneuromodulation) in order to provide a multicentre summary of population characteristics and treatment outcomes based on a standardized POL-CA questionnaire and methodology for various arrhythmias.",[153,154,155,156,157,158,159,160,161,162,163,164],"Vasovagal Syndrome VVS","Cardioinhibitory Carotid Sinus Syndrome CSS","Symptomatic Sinus Bradycardia SB or Atrioventricular Block AV","Postural Orthostatic Tachycardia Syndrome POTS","Orthostatic Hypotension","Inappropriate Sinus Tachycardia Syndrome IST","Vasospastic Angina","Microvascular Angina","Ventricular Arrythmia","Raynaud Phenomena","Autonomic Dysfunction","Autonomic Diseases",[166,167,168,169,170,171,172,173,174,175],"cardioneuroablation","cardiac sympathetic denervation","sinoatrial node sparing hybrid ablation","catheter ablation","neural stimulation","cardioneuromodulation","percutaneus stellate ganglion blockage","cardiac rehabilitation","cardiovascular autonomic tests","syncope","2025-09-21",{"date":178,"type":37},"2025-09-29",{"date":180,"type":37},"2024-11-21",{"date":93,"type":22},{"name":183,"class":184},"SABAMED Medical Center Ltd.","NETWORK",{"id":186,"slug":187,"hasResults":11,"nctId":188,"briefTitle":189,"officialTitle":190,"acronym":191,"eligibilityCriteria":192,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":193,"targetDuration":4,"studyType":56,"phases":195,"briefSummary":196,"conditions":197,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":202,"leadSponsor":204,"locationsCount":4},"100605485","tragus-stimulation-for-pots-treatment-100605485","NCT07163130","Tragus Stimulation for POTS Treatment","Transcutaneous Auricular Vagus Nerve Stimulation in Postural Tachycardia Syndrome: a Prospective Cross-over Study","TREAT-POTS","Inclusion Criteria:\n\n* Male or female patients aged ≥18 years\n* Diagnosis of POTS, defined as heart rate increase \\>30 beats\u002Fmin from supine within 10 minute of standing, in the absence of orthostatic hypotension (\\>20\u002F10 mm Hg fall in blood pressure), with chronic symptoms (\\>6 months), and in the absence of other acute causes of orthostatic tachycardia,\n* Signed written informed consent by the patient for participation in the study and agreement to comply with the study procedures and the follow-up schedule.\n\nExclusion Criteria:\n\n* Hypertension (\\>150 mmHg systolic and \\>100 mmHg diastolic) based on history or findings at screening.\n* Orthostatic hypotension (consistent drop in blood pressure \\>20\u002F10 mmHg with 10 min of standing)\n* History or presence of significant neurological, immunological, or hematological disorders\n* Cardiovascular disease, such as myocardial infarction within 6 months\n* Patients on renal dialysis.\n* Life expectancy of \\\u003C12 months\n* Currently pregnant women or women planning on becoming pregnant ≤ 5 months\n* Patients with active implants (such as a cardiac pacemaker, implantable cardioverter-defibrillator, or a cochlear implant)\n* Known channelopathy such as Brugada syndrome, long QT syndrome, or Catecholaminergic monomorphic ventricular tachycardia.\n* Episodic or permanent complete heart block or 2nd degree atrioventricular block Mobitz 2 or bifascicular block with concurrent 1st degree atrioventricular block\n* Congestive heart failure New York Heart Association class IV, defined as shortness of breath at rest, which is refractory to medical treatment (not responding to treatment)\n* Inability to comply with the protocol.",{"count":194,"type":22},24,[81],"Postural Tachycardia Syndrome (POTS) is a form of dysautonomia characterized by an abnormal cardiovascular response to orthostatic challenges. Individuals afflicted with POTS typically exhibit a heart rate increase of more than 30 beats per minute (bpm) within 10 minutes of assuming an upright posture from a supine or sitting position. This abnormal response is often accompanied by symptoms, such as orthostatic intolerance, dizziness, weakness, fatigue, and, in certain instances, syncope. Lately, there is revived interest in POTS, as it has been quite frequently reported as a manifestation of autonomic dysfunction among patients with long COVID. POTS primarily affects the younger demographic, particularly women, and its pathophysiology appears to be multifactorial, involving autonomic neuropathy, hyperadrenergic state, and inadequate blood volume regulation. Diagnostic criteria commonly include a sustained heart rate increase without significant orthostatic hypotension. The pathophysiological mechanisms of POTS are complex and not fully elucidated. Management strategies encompass lifestyle modifications, exercise programs, and pharmacotherapy, but their efficacy is modest.\n\nTranscutaneous auricular vagus nerve stimulation (tVNS) is an emerging therapeutic modality in cardiovascular diseases. tVNS has been shown to exert antiadrenergic and anti-inflammatory effects in humans. Recently, tVNS has been tested in experimental and human POTS, leading to improved autonomic function, reduction of anti-autonomic autoantibodies and inflammatory cytokines. However, the exact patient characteristics that would identify a patient likely to respond to tVNS as well as further mechanistic and clinical endpoints with tVNS have not been explored.\n\nThe aim of this study is to assess and characterize in detail the effect of tVNS in patients with POTS. This is a prospective crossover study in patients with POTS. The expected study duration is approximately 15 months from the time the first subject is enrolled to study termination. Patient enrollment is planned to take place at 3-4 major centers in Greece.",[28],"2025-09-01",{"date":200,"type":37},"2025-09-09",{"date":198,"type":22},{"date":203,"type":22},"2027-01-31",{"name":205,"class":44},"Aristotle University Of Thessaloniki",{"id":207,"slug":208,"hasResults":11,"nctId":209,"briefTitle":210,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":56,"phases":216,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":45},"100594444","pots-flow-interplay-between-gut-hormones-and-autonomic-postprandial-blood-flow-regulation-in-patients-with-pots-100594444","NCT07019519","POTS-FLOW: Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS","Interplay Between Gut Hormones and Autonomic Postprandial Blood Flow Regulation in Patients With POTS","GA22","Inclusion Criteria POTS patients:\n\n* Previously diagnosed with POTS in tilt test or active stand-test (either newly diagnosed within last 3 months or in new tilt test\u002Factive stand test during screenings visit)\n* Reproducible orthostatic intolerance with raise in HR on \\>30 bpm when standing within 10 minutes of change of supine to standing in age \\>19 years or \\>40 bpm in age 18-19 years.\n* POTS symptoms\u002Forthostatic intolerance\n* Age 18-50\n* Waist ratio \\\u003C180 cm\n\nExclusion Criteria:\n\n* Chronic illness\n* Metallic implants\n* Above 10 alcoholic drinks or week or substance abuse\n* Other types of sinus tachycardia or heart disease\n* Liverenzymes two times above normal values\n* Decreased kidney function eGFR \\\u003C90 or elevated kreatinkinasis\n* Thyroid disease or TSH out of reference\n* Uncontrollable low or high blood pressure\n* Blood vessels that cannot be visualized on MR\n* Any disease that might influence the health of the participant during the study or participants that receives medicine that cannot be paused for 36 hours\n\nInclusion Criteria:\n\n* Age 18-50\n* Waist ratio \\\u003C180 cm\n* Matched a POTS patient in age, sex and BMI\n\nExclusion Criteria:\n\n* Chronic illness\n* Metallic implants\n* Above 10 alcoholic drinks or week or substance abuse\n* POTS; other types of sinus tachycardia or heart disease\n* Liverenzymes two times above normal values\n* Decreased kidney function eGFR \\\u003C90 or elevated kreatinkinasis\n* Thyroid disease or TSH out of reference\n* Uncontrollable low or high blood pressure, Orthostatic hypotension\n* Blood vessels that cannot be visualized on MR\n* Any disease that might influence the health of the participant during the study or participants that receives medicine that cannot be paused for 36 hours","50 Years",{"count":79,"type":22},[81],"This study will describe the interplay between the gut hormones GIP and CCK and their regulation of blood flow to the large vessels in patients with Postural Orthostatic Tachycardia Syndrome (POTS) and GIP, CCK and GLP-1 in healthy. This is addressed by hormone infusions during MR-scans of the abdomen and intake of oral glucose.",[28,219],"Healthy",[85,221,222,223,224,225,226,227,228,229,230],"POTS","Glucose-dependent insulinotropic polypeptide","GIP","Glucagon-like peptide-1","Glucagon-like peptide-2","GLP-1","GLP-2","CCK-8","Cholecystokinin","Splanchnic Blood Flow","2025-06-10",{"date":233,"type":37},"2025-06-13",{"date":235,"type":37},"2025-03-15",{"date":237,"type":22},"2026-09-30",{"name":239,"class":44},"University of Copenhagen",{"id":241,"slug":242,"hasResults":11,"nctId":243,"briefTitle":244,"officialTitle":245,"acronym":4,"eligibilityCriteria":246,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":56,"phases":249,"briefSummary":250,"conditions":251,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":256,"completionDateStruct":257,"leadSponsor":259,"locationsCount":4},"100592660","effects-of-auricular-vagus-nerve-stimulation-combined-with-slow-paced-breathing-on-individuals-with-postural-orthostatic-tachycardia-syndrome-100592660","NCT06996314","Effects of Auricular Vagus Nerve Stimulation Combined With Slow-paced Breathing on Individuals With Postural Orthostatic Tachycardia Syndrome.","Effects of Transcutaneous Auricular Vagus Nerve Stimulation Combined With Slow-Paced Diaphragmatic Breathing on Postural Tachycardia Syndrome: A Randomized Controlled Trial","Inclusion Criteria:\n\nFormal diagnosis of Postural Orthostatic Tachycardia Syndrome (POTS), confirmed by clinical criteria: a sustained increase in heart rate (HR) of ≥30 bpm within 10 minutes of standing, without orthostatic hypotension.\n\nHistory of POTS diagnosis for at least 6 months.\n\nParticipants with Post-acute COVID-19 syndrome may be included if they meet the formal POTS criteria. These participants will be stratified based on the presence or absence of Post-Exertional Malaise (PEM).\n\nStable medication for POTS (same dosage\u002Fclass) for at least 4 weeks before enrollment.\n\nWillingness and ability to provide informed consent.\n\nScreening of Undiagnosed Participants:\n\nSuspected POTS based on clinical symptoms (e.g., dizziness, fatigue, syncope, brain fog, palpitations, exercise intolerance) persisting ≥6 months.\n\nPreliminary Schellong test by study team.\n\nIf criteria are met, referral to a specialist (neurology or cardiology) for diagnostic confirmation.\n\nInclusion only after specialist-confirmed POTS diagnosis.\n\nExclusion Criteria:\n\nSignificant hypertension (BP \\>150\u002F100 mmHg supine or standing).\n\nOrthostatic hypotension: drop in BP \\>20 mmHg systolic or \\>10 mmHg diastolic upon standing.\n\nRecent stroke or myocardial infarction (within 6 months).\n\nSignificant immunological or hematological disorders.\n\nSevere anemia (hematocrit \\\u003C28%).\n\nHistory of vagotomy.\n\nPregnancy or lactation.\n\nInability or unwillingness to provide informed consent.","65 Years",{"count":21,"type":22},[81],"This study investigates a non-pharmacological treatment approach for Postural Orthostatic Tachycardia Syndrome (POTS), a disorder of the autonomic nervous system characterized by an excessive increase in heart rate upon standing. POTS is commonly associated with symptoms such as dizziness, fatigue, cognitive difficulties, sleep disturbances, as well as anxiety and depression, which significantly impair quality of life.\n\nThis randomized, controlled clinical trial aims to evaluate whether combining transcutaneous auricular vagus nerve stimulation (taVNS) with slow-paced diaphragmatic breathing (at 0.1 Hz) provides greater therapeutic benefit compared to taVNS alone or sham stimulation.\n\nA total of 100 participants will be recruited and randomly assigned to one of four groups (25 per group):\n\ntaVNS with slow-paced breathing,\n\ntaVNS with spontaneous (normal) breathing,\n\nsham taVNS with slow-paced breathing, or\n\nsham taVNS with spontaneous breathing.\n\nParticipants will perform the intervention daily at home for a duration of 12 weeks. Medical and psychological assessments will be conducted before and after the intervention, including measurements of heart rate, inflammatory cytokines, and patient-reported outcomes on sleep, mood, and quality of life.\n\nThe study is conducted at the Center for Public Health, Medical University of Vienna, and is open to individuals diagnosed with POTS, including those with coexisting Post-COVID-19 syndrome.",[28,252],"Post-acute COVID-19 Syndromes","2025-05-30",{"date":255,"type":37},"2025-06-04",{"date":198,"type":22},{"date":258,"type":22},"2028-08-31",{"name":260,"class":44},"Ali Kapan",{"id":262,"slug":263,"hasResults":11,"nctId":264,"briefTitle":265,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":268,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":270,"conditions":271,"keywords":273,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":279,"lastUpdatePostDateStruct":280,"startDateStruct":282,"completionDateStruct":284,"leadSponsor":286,"locationsCount":4},"100592369","auto-immune-contribution-in-symptom-based-sensory-and-autonomic-disorders-100592369","NCT06992531","Auto-immune Contribution in Symptom-based Sensory and Autonomic Disorders","ACSSAD","Inclusion Criteria:\n\n* Between 18 and 80 years of age.\n* In the capacity to understand and sign an Informed Consent Form.\n* Willing and able to comply with scheduled visits and study procedures.\n* Diagnostic criteria for participants:\n* PoTS: following Heart Rhythm Society Expert Consensus Statement criteria, 2015, with or without comorbid FMS.\n* FMS: following the American College of Rheumatology criteria 2016, with Fibromyalgia Impact Questionnaire (FIQ) exceeding 50, and with an average pain intensity exceeding 5.5.\n* Healthy volunteers: no diagnosed autoimmune, chronic pain, or dysautonomia condition.\n\nExclusion Criteria:\n\n* Previous diagnosis of an established autoimmune condition or dermatological conditions affecting skin afferents (e.g. psoriasis, lupus, vitiligo, dermatitis…).\n* Application of local anaesthetics or steroid injections within 35 days prior to the microneurography visit.\n* Current use of anticoagulant therapy.\n* History of peripheral neuropathy or conditions usually associated with peripheral neuropathy, such as Diabetes Mellitus, Vitamin B12 deficiency, Lyme disease, a screen positive for hepatitis B surface antigen, hepatitis C virus antibody, or antibodies against human immunodeficiency viruses 1 and 2.\n* Pregnancy.\n* Difficulties in locating the nerve (i.e. nerve cannot be seen or palpated) or previously known trauma or surgery in the area innervated will be a criterion for the exclusion of the participant for this part of the study.\n* History of regular alcohol consumption (exceeding 14 units per week) or recent alcohol consumption exceeding 14 units per week over the last 6 months (14 units is equivalent to 7 pints \\[568 mL\u002Fpint\\] of beer at 3.6% alcohol by volume or 6 standard glasses \\[176 mL\u002Fglass\\] of wine at 12% alcohol by volume).\n* Excessive consumption of caffeinated beverages (e.g., coffee, tea, cola, energy drinks), is defined as greater than 6 servings per day (1 serving\u002F236 mL equals approximately 120 mg of caffeine).\n* A history of drug abuse or addiction within 2 years before study, current regular or recreational use of marijuana (or any cannabis derivative).",{"count":269,"type":22},250,"Postural Orthostatic Tachycardia Syndrome (PoTS) is a condition where the heart rate increases when standing up, causing symptoms like dizziness and fainting. It primarily affects young women and can be very disabling, impacting daily life. In addition to the typical symptoms related to standing, people with PoTS also experience unexplained pain and fatigue, which worsen their quality of life. The exact causes of PoTS are still unknown, but it is often triggered by viral infections and some PoTS patients show signs of immune system involvement, such as the presence of certain autoantibodies and other autoimmune conditions. Research on other chronic pain disorders, including fibromyalgia syndrome (FMS), has found that autoantibodies can cause pain by affecting how the nerves work. This study aims to investigate if similar immune-related mechanisms are behind the widespread pain seen in PoTS. This study will also look at how PoTS affects the nervous system by testing nerve activity in participants and assessing the number of nerve fibres in the skin, to check if similar changes can be seen in mice. This study will also involve participants with fibromyalgia syndrome and healthy volunteers.",[28,272],"Fibromyalgia (FM)",[274,275,276,277,278],"Postural orthostatic Tachycardia Syndrome","Fibromyalgia Syndrome","Widespread pain","Autoantibodies","Autonomic and sensory functions","2025-05-27",{"date":281,"type":37},"2025-05-28",{"date":283,"type":22},"2025-10",{"date":285,"type":22},"2030-10",{"name":287,"class":44},"King's College London",{"id":289,"slug":290,"hasResults":11,"nctId":291,"briefTitle":292,"officialTitle":293,"acronym":294,"eligibilityCriteria":295,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":77,"enrollmentInfo":296,"targetDuration":4,"studyType":56,"phases":298,"briefSummary":299,"conditions":300,"keywords":4,"overallStatus":130,"whyStopped":4,"lastUpdateSubmitDate":301,"lastUpdatePostDateStruct":302,"startDateStruct":304,"completionDateStruct":306,"leadSponsor":308,"locationsCount":45},"100588048","counterpressure-maneuvers-in-postural-orthostatic-tachycardia-syndrome-100588048","NCT06936319","Counterpressure Maneuvers in Postural Orthostatic Tachycardia Syndrome","Physical Counterpressure Maneuvers in Postural Orthostatic Tachycardia Syndrome (POTS) - a Monocentric, Randomized Controlled Trial","CPM_in_POTS","Inclusion Criteria:\n\n* POTS diagnosis\n* 18 to 80 years of age at time of consent\n* stable medication in the seven days prior to the baseline visit\n* able to provide written informed consent\n\nExclusion Criteria:\n\n* participation in other interventional trials\n* pregnant or breastfeeding females\n* on treatment with vasoactive medications including medications for heart rate control\n* acute infections at the time of enrolment or in the two weeks before\n* acute pain\n* surgery in the last three months\n* inability or contraindication for performing hip and knee flexion, hip adduction or squatting\n* inability to stand for at least two minutes\n* Any other cardiological, internal, psychiatric or neurological condition, which may prevent engagement in the sturdy procedures in the judgement of the investigator",{"count":297,"type":22},40,[81],"The present study evaluates whether performing a 14-days counter pressure maneuvers (CPM)-biofeedback training improves the symptomatic burden (primary objective) and secondarily the interference of POTS symptoms with daily activities, fatigue, and health-related quality of life of individuals with POTS compared to best clinical practice non-pharmacological measures. Secondary in-laboratory objectives are to assess the influence of CPM on the supine-to-standing heart rate (HR) and blood pressure (BP) changes as well as on the severity of orthostatic intolerance after performing CPM for two minutes compared to a baseline (intervention-free) active standing test, and to assess the safety and tolerability of CPM-biofeedback training in individuals with POTS.\n\nThis is a monocentric, proof-of-concept, 1:1 randomized, controlled trial with rater-blinded evaluation of the hemodynamic effect of CPM in 40 individuals suffering from POTS.\n\nAll study participants will receive detailed counselling on CPM and other behavioral and non-pharmacological measures to combat POTS symptoms in daily life and will be invited to practice them regularly (best clinical practice). Participants randomized to the interventional arm will receive a CPM-biofeedback training session in the autonomic function laboratory at the Department of Neurology of the Innsbruck Medical University to learn four different CPM under continuous HR and BP monitoring. The CPM-biofeedback training will consist of a baseline 2-minutes active standing and the following four different physical maneuver: leg crossing and muscle tensing, heel raises (10 tiptoeing per minute), squatting, unilateral handgrip (20 times a minute).\n\nThe trial foresees three study visits for both the interventional and the control arm (screening and baseline on-site, as well as a telephone visit 14 days later). For the interventional trial arm, two additional visits are planned (CPM-biofeedback training session in the autonomic function laboratory and a follow-up telephone visit 7 days later).\n\nTo evaluate the baseline to day-14 change in symptom severity, the Malmö POTS Score (MAPS) total score (primary endpoint) and the MAPS single items, Vanderbilt Orthostatic Symptom Score, Orthostatic Grading Scale, Fatigue Severity Scale and Health-related Quality of Life Questionnaire (EuroQol -EQ-5D-5L ) will be administered.",[28],"2025-04-29",{"date":303,"type":37},"2025-05-02",{"date":305,"type":37},"2025-01-15",{"date":307,"type":22},"2025-12-31",{"name":309,"class":44},"Medical University Innsbruck"]